OPK.TA

OPKO Health, Inc. is a global healthcare enterprise operating across the diagnostics and pharmaceutical sectors. Its reach extends across the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. Within its Diagnostics segment, the company notably operates BioReference Laboratories, a provider of comprehensive laboratory testing services. These services are crucial for the identification, diagnosis, assessment, monitoring, and management of various diseases. The offerings span specialized areas like esoteric testing, molecular diagnostics, anatomical pathology, genetic analyses, women's health, and correctional healthcare, catering to a diverse clientele including medical practices, outpatient clinics, hospitals, corporate entities, and governmental agencies. This segment also features an innovative diagnostic instrument system designed to yield rapid blood test results directly at the point of care, alongside its distinctive 4Kscore testing for prostate cancer. The Pharmaceutical segment is actively engaged in the development and commercialization of therapeutic products. Its portfolio includes Rayaldee, prescribed for adults suffering from secondary hyperparathyroidism associated with stage 3 or 4 chronic kidney disease and concomitant vitamin D insufficiency. The pipeline features OPK88004, an oral selective androgen receptor modulator, and OPK88003, a peptide administered once-weekly, currently undergoing Phase IIb trials for managing type 2 diabetes and related obesity. Another key candidate is hGH-CTP, a once-weekly human growth hormone injection, which has successfully concluded Phase III clinical trials in collaboration with Pfizer, Inc. A strategic objective for this segment is the development and market introduction of proprietary, extended-duration formulations of established therapeutic proteins. Beyond these core activities, OPKO Health also supplies specialized active pharmaceutical ingredients (APIs). The company undertakes the development, manufacturing, marketing, and sales of a broad spectrum of products, including pharmaceuticals, nutraceuticals, veterinary treatments, and ophthalmic preparations. Furthermore, it commercializes food supplements and various over-the-counter (OTC) products, and is involved in the manufacture and sale of generic pharmaceutical products. OPKO Health additionally engages in the import, marketing, distribution, and sale of an extensive array of pharmaceutical products targeting numerous indications, such as cardiovascular conditions, infectious diseases (vaccines, antibiotics), gastrointestinal ailments, and hormonal disorders. Support for its pharmaceutical ventures is provided by operational platforms situated in Ireland, Chile, Spain, and Mexico. Established in 1991, OPKO Health maintains its corporate headquarters in Miami, Florida.